155. Bad Hairdo to Good HairDAO: Andrew Verbinnen on Reversing Hairloss Through Decentralization

Episode notes

We sit down with Andrew Verbinnen, founder of HairDAO, who's revolutionizing how we approach hair loss research and treatment. After experiencing hair loss himself at nineteen, Andrew discovered that androgenetic alopecia - affecting 95% of hair loss cases - receives almost no funding because it's classified as cosmetic rather than a disease. By creating a patient-led biotech organization combining a thriving online community with an in-house high-throughput lab, HairDAO has driven research costs down from $250,000 per study to just $6,000 while accelerating results from two years to one month. Andrew shares how they've developed proprietary treatments available through their telehealth platform Anagen, built a unique human hair follicle organ culture model that's providing unprecedented data on fully intact human tissue, and created a token-based governance system where patients vote on which research to fund. We explore the blurring lines between pharmaceuticals and consumer products, the power of patient empowerment in driving innovation, and why Andrew believes the hair follicle data they're generating could unlock treatments for conditions far beyond hair loss.

• 186. N.Y. Tech Week Live Demo: Engineering the Future of Manufacturing with Roebling's Brentan Alexander72 / 100
• 185. Brick Happens: Chris Maurer of Redhouse Studio Redesigns Remote Living for Earth and Mars75 / 100
• 184. The Multiverse of Microbes: Henry Lee on Building Cultivarium and Training with Titans65 / 100
• 183. The American Biotech Blueprint: Senator Todd Young on Biodiversity as National Security
• 182. SynBioBeta 2026 Recap, It's Biologist Approved